Hospital Resource Utilization and Costs of Inappropriate Treatment of Candidemia
Authors:
- 1 April 2010
- journal article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 30 (4) , 361-368
Abstract
Study Objectives. To evaluate the impact of inappropriate therapy—defined as delayed antifungal therapy beyond 24 hours from culture collection, inadequate antifungal dosage, or administration of an antifungal to which an isolate was considered resistant—on postculture hospital length of stay and costs, and to evaluate the relationship between modifiable risk factors, including failure to remove a central venous catheter, antifungal delay, and inadequate dosage, for an additive effect on hospital length of stay and costs.Design. Single‐center retrospective cohort study.Setting. 1250‐bed academic medical center.Patients. One hundred sixty‐seven consecutive adult patients admitted between January 2004 and May 2006 with culture‐confirmed Candida bloodstream infections that occurred within 14 days of hospital admission and who received at least one dose of antifungal treatment.Measurements and Main Results. Patients were stratified according to appropriateness of antifungal therapy. Appropriate therapy was defined as initiation of an antifungal to which the isolated pathogen was sensitive in vitro within 24 hours of positive culture collection, in addition to receipt of an adequate dose as recommended by the Infectious Diseases Society of America and the antifungal package insert. Postculture length of stay was the primary outcome and hospital costs the secondary outcome. An evaluation of modifiable risk factors was performed separately. Data were analyzed for 167 patients (22 in the appropriate therapy group and 145 in the inappropriate therapy group). Postculture length of stay was shorter in the appropriate therapy group (mean 7 vs 10.4 days, p=0.037). This correlated with total hospital costs that were lower in the appropriate therapy group (mean $15,832 vs $33,021, pConclusion. Inappropriate therapy for Candida bloodstream infection occurring within 14 days of hospitalization was associated with prolonged postculture length of stay and increased costs. A rise in costs, but not length of stay, was noted with increasing modifiable risk factors.Keywords
This publication has 21 references indexed in Scilit:
- Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2009
- Treatment-related risk factors for hospital mortality in Candida bloodstream infections*Critical Care Medicine, 2008
- Inappropriate therapy for methicillin-resistant Staphylococcus aureus: Resource utilization and cost implications*Critical Care Medicine, 2008
- Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2005: an 8.5-Year Analysis of Susceptibilities of Candida Species and Other Yeast Species to Fluconazole and Voriconazole Determined by CLSI Standardized Disk Diffusion TestingJournal of Clinical Microbiology, 2007
- Biofilm Production by Candida Species and Inadequate Antifungal Therapy as Predictors of Mortality for Patients with CandidemiaJournal of Clinical Microbiology, 2007
- Economic implications of an evidence-based sepsis protocol: Can we improve outcomes and lower costs?*Critical Care Medicine, 2007
- Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemiaCritical Care Medicine, 2007
- Epidemiology of Invasive Candidiasis: a Persistent Public Health ProblemClinical Microbiology Reviews, 2007
- Time to Initiation of Fluconazole Therapy Impacts Mortality in Patients with Candidemia: A Multi‐Institutional StudyClinical Infectious Diseases, 2006
- Hospital-acquired candidemia. The attributable mortality and excess length of stayArchives of internal medicine (1960), 1988